Tuba Ilgar

Dr. Tuba Ilgar

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
TITuba Ilgar
Tuba Ilgar
AÖAybegüm Özşahin
Aybegüm Özşahin
Background: Blood culture contamination is a significant problem that can lead to misdiagnosis, unnecessary antibiotic use, and increased workload. This study aimed to determine the blood culture contamination rates in a tertiary hospital and to evaluate the factors associated with contamination. Methods: This retrospective descriptive study included blood culture samples collected at a tertiary hospital between January 2023 and December 2023. Cultures from patients aged ≥ 18 years were evaluated. Growth of coagulase-negative staphylococci (CoNS) and other skin flora agents that were not considered clinically significant were classified as contamination. Contamination risk factors, including the sampling unit, sampling period, and healthcare personnel who collected the cultures, were evaluated. Results: A total of 7716 blood cultures from 2388 patients were included. 11.8% of the cultures were defined as contaminated. Contamination rates were found to be significantly higher in internal medicine wards (12.5%) and intensive care units (13.5%) compared to surgical wards (3.6%) ( p < 0.001). In logistic regression analysis, the risk of contamination was found to be 3 times higher in blood cultures taken from internal medicine wards and 4.1 times higher in ICUs compared to surgical wards ( p < 0.001 and p < 0.001, respectively). Blood cultures obtained by intern doctors (sixth-year medical students) were independently associated with contamination (OR = 1.68; p < 0.001). The risk of contamination was higher in blood cultures taken between July and December (OR = 1.23; p = 0.004). Conclusion: Blood culture contamination is a multifactorial problem influenced by factors such as the sampling unit and staff experience. These findings highlight the need for targeted quality improvement interventions, particularly structured training for newly rotating clinical staff. Clinical trial registration: Not applicable.

19 August 2026 in Mediterranean Journal of Infection Microbes and Antimicrobials
Verified
Journal Article
Closed access
PDF file
TITuba Ilgar
Tuba Ilgar
AÖAybegüm Özşahin
Aybegüm Özşahin
SMSudem Mahmutoğlu-Çolak
Sudem Mahmutoğlu-Çolak
IYİlKnur E. Yıldız
İlKnur E. Yıldız
UKUğur Kostakoğlu
Uğur Kostakoğlu
AEAyşe Ertürk
Ayşe Ertürk
Age-Specific Anti-HBs Seropositivity Among Individuals Eligible for the Childhood Hepatitis B Vaccination Program: A Single-Center Study - Mediterranean Journal of Infection Microbes and Antimicrobials

22 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SÇSUDEM MAHMUTOĞLU ÇOLAK
SUDEM MAHMUTOĞLU ÇOLAK
TITuba Ilgar
Tuba Ilgar
EÖESRA ÖZKAYA
ESRA ÖZKAYA
MYMERVE HÜNER YIGIT
MERVE HÜNER YIGIT
HDHilal Durmuş
Hilal Durmuş
Zihni Acar YazıcıZihni Acar Yazıcı
Zihni Acar Yazıcı
The pathogenesis of COVID-19 highlights a complex relationship between disease severity and neutralizing antibodies (NAbs). We aimed to investigate the relationship between total NAb (tNAb) levels, presence of potential neutralization inhibiting antibodies (pNAbs), and the clinical outcomes of COVID-19 patients. Patients aged ≥18 years diagnosed between October 2021 and September 2022 were grouped by symptom severity. Blood samples were taken at two time points and data on demographics, epidemiology, and vaccination were recorded. The tNAbs and pNAbs were measured by enhanced chemiluminescence assay and surrogate virus neutralization test, respectively. Among 68 tNAbs and 52 pNAbs results, 26 (38.2%) patients had a severe infection. The 28-day mortality rate was 16.2% (n=11). The tNAbs levels in the control blood samples (CBS) were significantly higher than those of the admission blood samples (ABS) (p<0.001). The statistical analysis showed no relation between disease severity and tNAb titers. Vaccinated patients had significantly higher tNAbs in ABS and CBS (p<0.001 and p<0.001, respectively). Presence of pNAbs in the ABS correlated with lower 28-day mortality (p=0.026) and milder disease course (p=0.041). Although these findings support a correlation between tNAbs and disease severity and mortality, these seem to be related to their formation rather than their effect on the clinical outcomes.

22 July 2024
Verified
Book
Open access
PDF file
NHNur Hursoy
Nur Hursoy
HGHamide Betül Gün
Hamide Betül Gün
VÖVacide Aşık Özdemir
Vacide Aşık Özdemir
YAYağmur Akbal
Yağmur Akbal
FAFiliz Akturk Acar
Filiz Akturk Acar
Tolga MercantepeTolga Mercantepe
Tolga Mercantepe
X-Işını Öncesi Dönemde Hastalıklara Yaklaşım Nur HÜRSOY Unutulmuş Tıbbi Muayene Yöntemleri Hamide Betül GÜN Hemşirelik Bakımında Terk Edilen, Unutulan Uygulamalar Vacide AŞIK ÖZDEMİR Yağmur AKBAL Unutulmuş Doğum Yöntemleri ve Bebek Bakımı Filiz AKTÜRK ACAR Unutulmuş Biyokimyasal Laboratuvar Tanı Teknikleri Hülya KILIÇ Uygulaması Korkunç Sonuçları Olan İlaçlar Atilla TOPÇU Unutulan Psikiyatrik Tedaviler Uğur TEKEOĞLU Çiçek HOCAOĞLU Unutulmuş Tedavi Yöntemi Psikoşirurji ve “Phineas Gage’ Vakasının Etkisi Ayhan KANAT Serdar DURMAZ Psikiyatrik Bozukluklarda Kullanılan Cerrahi Tedaviler Burak OKUMUŞ Kara Ölüm ve Karanlık Tedaviler Cihad DÜNDAR İnsanlık Tarihinin Civa ile İmtihanı Hatice Nilden ARSLAN DDT (Dikloro Difenil Trikloroetan) Kullanımı ve Sonuçları Özlem TERZİ Aşı ve Aşılamanın Tarihçesi Handan DUMAN Eski Çağlarda Enfeksiyon Hastalıklarının Tedavisi İlknur ESEN YILDIZ Sudem M. ÇOLAK Tuba İLGAR Aybegüm ÖZŞAHİN Obezite Tedavisinde Unutulan Uygulamalar Ayten YILMAZ YAVUZ Gamzegül ALTAY Eski Çağlarda Göğüs Hastalıkları Tedavi ve Tanı Yöntemleri Esra ARSLAN AKSU Endokrinoloji ve Diyabetin Geçmişi Damla TÜFEKÇİ Katarakt Cerrahisinde Dünden Bugüne Fatma SÜMER Kulak Burun Boğaz Hastalıklarında Terk Edilmiş Cerrahiler Mehmet BİRİNCİ Özlem ÇELEBİ ERDİVANLI Genel Cerrahide Cerrahi Morbiditesi Nedeniyle Terkedilmiş Ameliyatlar Ahmet PERGEL Bahri KALYONCU Unutulan Ürolojik Cerrahi Girişimler ve Medikal Tedaviler Selim YAZAR Selma DURMAZ Hüseyin EREN Geçmişte Jinekoloji, Akıl Almaz Fertilite Tedavileri ve Doğum Yöntemleri Yeşim BAYOĞLU TEKİN Eski ve Unutulmuş Ortopedik Tedavilerin Tarihi ve Gelişimi Cengiz KAZDAL Ahmet Tunahan YILMAZ Korkunç Anestezi Yöntemleri Leyla KAZANCIOĞLU Anestezide Unutulmuş Tedaviler Şule BATÇIK Hızır KAZDAL Unutulmuş Adli Tıp Uygulamaları Hüseyin Çetin KETENCİ Muhammed Ali ÖZDEMİR Geçmişten Günümüze Kan Transfüzyonları; 350 Yılı Aşan Bir Hikaye Nurettin TIĞ Sinan SARAL Unutulmuş Radyolojik Yöntemler Gülen BURAKGAZİ Geçmişten Günümüze Ağrı Tedavisinde Elektroterapinin Yeri: Biyofiziksel Bakış Açısı Hamit YILMAZ Kanser Tedavisinde Eskiden Kullanılan Kemoterapi Dışı Onkolojik Tedaviler Murat ALAN Recep TÜRKEL Bülent ÇETİN Kanserde Unutulmuş Tedaviler Elanur KARAMAN Radyoterapide Kullanılan İmmobilizasyon Cihazlarının Gelişimi: Tarihsel Perspektif Sema YILMAZ RAKICI Ömer YAYLA Sidem GÜL Neslihan Nisa RAKICI Unutulmuş Radyoterapi Uygulamaları Özgür ALTMIŞDÖRTOĞLU Radyasyon Onkolojisinde Hesapsız Radyasyon Hesapları Hilal KIZILTUNÇ ÖZMEN Burcu SAĞLAM ALAN Tıp Tarihi ve Etik Özelindeki İçerikler Hakkında Kısa Bir Değerlendirme Nuray DEMİRCİ GÜNGÖRDÜ Seçil ÖZÇİFTÇİ Çağatay ÜSTÜN Geçmişten Günümüze Embriyolojiye Bakış Burcu DELİBAŞ Zülkar ÖZDEN Levent TÜMKAYA Histoloji Disiplininin Tarihi Zülkar ÖZDEN Tolga MERCANTEPE Levent TÜMKAYA

30 June 2025 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
TITuba Ilgar
Tuba Ilgar
AÖaybegüm özşahin
aybegüm özşahin
SÇSudem Mahmutoğlu Çolak
Sudem Mahmutoğlu Çolak
IYİlKnur Esen Yıldız
İlKnur Esen Yıldız
UKUğur Kostakoğlu
Uğur Kostakoğlu
AEAyşe Ertürk
Ayşe Ertürk
Introduction: Prediction of HBeAg loss is crucial for understanding the prognosis of chronic hepatitis B (CHB) and determining when to discontinue treatment. We aimed to identify factors predicting HBeAg clearance in patients undergoing antiviral treatment for HBeAg-positive CHB Methodology: This retrospective study included patients who started antiviral treatment for HBeAg-positive CHB from January 1, 2008, to December 31, 2022, with at least one year of follow-up. We evaluated age, platelet count, treatment duration, ALT × Upper limit of normal (ULN), AST × ULN, AST/ALT ratio, Albumin-Bilirubin grade (ALBI), Platelet-Albumin-Bilirubin grade (PALBI), AST-Platelet ratio index (APRI), and Fibrosis-4 (FIB-4) parameters. ROC analysis was used to assess these parameter's ability to predict HBeAg loss. Results: Ninety-four patients were included, 43 (45.7%) of whom were female. HBeAg clearance occurred in 32 (34%) patients. Treatment duration was significantly longer in patients with HBeAg clearance (p = 0.003). Patients with HBeAg clearance had significantly higher median age, fibrosis score (FS), APRI, and FIB-4 values (p = 0.028, p = 0.024, p = 0.008, and p = 0.003, respectively) and lower mean platelet count (p = 0.010) at treatment initiation. ROC analysis identified age, FS, APRI, FIB-4, and platelet count as significant predictors, with APRI having the highest area under the curve (AUC = 0.771, p = 0.007, sensitivity 65%, specificity 66.7% for the cut-off value of 0.71). Conclusions: This study highlights the potential of FIB-4, platelet count, and particularly APRI in predicting HBeAg clearance. These findings can aid clinicians in optimizing treatment strategies and improving patient outcomes.

8 March 2025 in Life
Verified
Journal Article
Open access
PDF file
SÇSUDEM MAHMUTOĞLU ÇOLAK
SUDEM MAHMUTOĞLU ÇOLAK
TITuba Ilgar
Tuba Ilgar
İBİlkay Bahçeci
İlkay Bahçeci
EÖESRA ÖZKAYA
ESRA ÖZKAYA
MYMERVE HÜNER YIGIT
MERVE HÜNER YIGIT
Zihni Acar YazıcıZihni Acar Yazıcı
Zihni Acar Yazıcı
The pathogenesis of COVID-19 highlights a complex relationship between disease severity and neutralizing antibodies (NAbs). We aimed to investigate the relationships among the total NAb (tNAb) levels, the presence of potential neutralization antibodies (pNAbs), and the clinical outcomes of COVID-19 patients. Patients aged ≥18 years diagnosed between October 2021 and September 2022 were grouped by symptom severity. Blood samples were taken at two time points and data on demographics, epidemiology, and vaccination were recorded. The tNAbs and pNAbs were measured by an enhanced chemiluminescence assay and a surrogate virus neutralization test, respectively. The tNAbs of 68 and the pNAbs of 52 patients were analyzed. Twenty-six (38.2%) patients had severe infection. The 28-day mortality rate was 16.2% (n = 11). The tNAb levels in the control blood samples (CBSs) were significantly higher than those of the admission blood samples (ABSs) (p < 0.001). The statistical analysis showed no relationship between disease severity and pNAbs. Vaccinated patients had significantly higher tNAbs in the ABSs and CBSs (p < 0.001 and p < 0.001, respectively). The presence of pNAbs in the ABSs was correlated with a lower 28-day mortality (p = 0.026) and a milder disease course (p = 0.041). Although these findings support a correlation between tNAbs and disease severity and mortality, their presence seems to be unrelated to favorable clinical outcomes.